Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
暂无分享,去创建一个
Bo Wang | John D. Chodera | Steven K. Albanese | Justin R. Cross | Gregory A. Petsko | Elli Papaemmanuil | Ross L. Levine | Bin Wu | Craig B. Thompson | Ariën S. Rustenburg | Noushin Farnoud | Martin S. Tallman | G. Petsko | J. Chodera | E. Papaemmanuil | S. Choe | M. Arcila | R. Levine | C. Thompson | M. Tallman | A. Intlekofer | A. Shih | N. Farnoud | J. Cross | Hui Liu | C. Famulare | Minal A. Patel | Z. Konteatis | Justin Taylor | N. Takemoto | Maria E. Arcila | E. Stein | Scott A. Biller | Alan H. Shih | Andrew M. Intlekofer | Abbas Nazir | Minal Patel | Christopher Famulare | Fabian M. Correa | Naofumi Takemoto | Vidushi Durani | Hui Liu | Justin Taylor | Mikhail Roshal | Sung Choe | Zenon D. Konteatis | Eytan M. Stein | M. Roshal | S. Biller | Bo Wang | M. Arcila | Vidushi Durani | Bin Wu | Abbas Nazir | C. Thompson | C. Thompson | R. Levine
[1] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[2] Alex M. Fichtenholtz,et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. , 2016, Blood.
[3] Benjamin L. Ebert,et al. (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.
[4] Anthony Stein,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[5] A rapid and efficient polyethylenimine-based transfection method to prepare lentiviral or retroviral vectors: useful for making iPS cells and transduction of primary cells , 2016, Biotechnology Letters.
[6] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[7] Young Lim Choi,et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.
[8] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[9] P. Pandolfi,et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. , 2014, Cell stem cell.
[10] W. Kaelin,et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.
[11] Fang Wang,et al. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.
[12] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[13] L. Sequist,et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies , 2015, Clinical Cancer Research.
[14] Hua Yang,et al. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. , 2017, Cancer discovery.
[15] Amy E. Hawkins,et al. DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.
[16] S. Lowe,et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition , 2013, Genes & development.
[17] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[18] Tak W. Mak,et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.
[19] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[20] P. Vyas,et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. , 2017, Blood.
[21] Francine E. Garrett-Bakelman,et al. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. , 2017, Cancer discovery.
[22] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[23] B. Honig,et al. A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.
[24] Z. Xiang,et al. On the role of the crystal environment in determining protein side-chain conformations. , 2002, Journal of molecular biology.